Table II.
Association between ADAM17 expression and clinicopathological characteristics of gliomas.
| ADAM17 expression | ||||
|---|---|---|---|---|
|
|
||||
| Clinicopathological features | Total, n | Low expression, n | High expression, n | P-value |
| Gender | ||||
| Male | 36 | 17 | 19 | 0.653 |
| Female | 24 | 11 | 13 | |
| Age | ||||
| <45 | 28 | 13 | 15 | 0.589 |
| >45 | 32 | 15 | 17 | |
| Tumor size, cm | ||||
| <4 | 24 | 9 | 15 | 0.185 |
| >4 | 36 | 19 | 17 | |
| Tumor location | 0.789 | |||
| Frontal | 18 | 8 | 10 | |
| Temporal | 23 | 12 | 11 | |
| Other | 19 | 8 | 11 | |
| Necrosis | ||||
| Absence | 31 | 12 | 19 | 0.154 |
| Presence | 29 | 16 | 13 | |
| KPS | ||||
| <80 | 33 | 14 | 19 | 0.320 |
| >80 | 27 | 14 | 13 | |
| WHO grade | ||||
| I–II | 25 | 18 | 7 | <0.005 |
| III–IV | 35 | 10 | 25 | |
ADAM17-positive expression rate was significantly correlated with the WHO classification of glioma grade. KPS, Karnofsky score; WHO, World Health Organization; ADAM17, a disintegrin and metalloproteinase-17; NS, not significant.